Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>New Oriental Education & Technology (<strong>EDU</strong>) disclosed in a regulatory following that, as part of the Registrant's efforts to streamline its corporate structure, the Registrant intends to wind up Shanghai Smart Words Software Technology Co., Ltd., a wholly-owned subsidiary of the Registrant in China and a company currently without business operations. Accordingly, the Registrant has removed Shanghai Smart Words as a party to the series of contractual arrangements whereby the Registrant, through its subsidiaries, controls and consolidates Beijing New Oriental Education & technology (Group) Co., Ltd. The rights and obligations of Shanghai Smart Words under the VIE Arrangements have been assumed by Beijing Decision Education & Consulting Co., Ltd., another wholly-owned subsidiary of the Registrant, which is an existing party to the VIE Agreements. Parties to the VIE Agreements entered into multiple agreements and amendments to effect the foregoing change.</li><li>Chugai Pharmaceutical, a member of the Roche (<strong>RHHBY</strong>) group, announced that it has filed a new drug application to the Ministry of Health, Labour and Welfare (MHLW), for Engineered anti PD-L1 monoclonal antibody «atezolizumab (genetic recombinant)» for the treatment of «unresectable advanced or recurrent non-small cell lung cancer (NSCLC).»</li><li>Cycle and Undertone, a division of Perion Network (<strong>PERI</strong>) announced an exclusive strategic partnership enabling Undertone to represent Cycle's branded content and social inventory to its prospective and current clients. In practice, the partnership will expand Undertone's suite of offerings to include Cycle's inventory and native ad offerings, as well as integrations into the media company's multiple ongoing video series.</li><li>Medivir AB (<strong>MVIR</strong>) announced that departing CEO, Niklas Prager, CEO designate Christine Lind and CFO Ola Burmark today have bought a total of 16.500 shares in Medivir. The purchase was made simultaneously with their sale of a total of 52.101 redemption rights, which were received in connection with the ongoing voluntary redemption program.</li></ul></td> </tr></table>"